IMS buys clinical trials support software firm

IMS says that by integrating its information on healthcare outcomes, providers and patients with DecisionView’s technology, it will be able to help clinical trial sponsors base their site selection and patient enrolment decisions on real-world data and benchmarks.

“Approximately 90% of clinical trials don’t finish on time, with trial enrolment cited as as the leading cause of delays,” said Andrew Kress, senior vice president of IMS Heathcare Value Solutions (HVS). “Through this acquisition we will enhance clinical trial productivity.”

DecisionView becomes part of HVS. President and CEO Linda Drumright (pictured) remains with the business.